黄斑浮腫の世界市場：2024年～2031年

概要

黄斑浮腫の世界市場は、2023年に79億3,269万米ドルに達し、2031年には148億7,470万米ドルに達すると予測され、予測期間2024年～2031年のCAGRは8.4%で成長する見込みです。

黄斑浮腫とは、網膜（目の奥にある光を感じる層）の一部が腫れることです。黄斑浮腫のある人は視界がぼやけますが、治療によって腫れを抑え、視力低下を防ぐことができます。

黄斑浮腫は、網膜の黄斑と呼ばれる部分に血管が漏れることで起こります。黄斑浮腫は、黄斑部に血管が漏れることで起こります。黄斑浮腫の原因にはさまざまな疾患があります。最も一般的なものは糖尿病性網膜症で、糖尿病の人に視力低下を引き起こす目の病気です。糖尿病網膜症が黄斑浮腫を引き起こす場合、糖尿病黄斑浮腫（DME）と呼ばれます。

黄斑浮腫の主な症状は、目のかすみと時間の経過とともに悪化する視力です。一般に、黄斑浮腫の検出は、フルオレセイン血管造影、光干渉断層計（OCT）、アムスラーグリッド法によって行われます。

市場力学：

促進要因

さまざまな年齢層における糖尿病有病率の上昇

複数の要因が世界の黄斑浮腫市場の需要を促進しています。糖尿病有病率の上昇は市場成長を促進します。現在、糖尿病に罹患する人が急増しており、これが黄斑浮腫の増加の主な原因となっています。

糖尿病黄斑浮腫は、黄斑浮腫全体の症例の中で最も頻繁に記録される症例の一つです。NCBIによると、米国では40歳以上で糖尿病を患っている人の3.8％が糖尿病黄斑浮腫に罹患しています。糖尿病に罹患している全世界の人口では、約4～7％の人が糖尿病黄斑浮腫に罹患しています。

阻害要因

世界の黄斑浮腫市場もまた、いくつかの課題と抑制要因に直面しています。主な阻害要因の1つは、黄斑浮腫の治療や療法にかかる費用が高額であることで、特に低所得者や十分な治療を受けていない地域の患者の治療へのアクセスが制限される可能性があります。さらに、規制上のハードルや償還政策が新たな糖尿病黄斑浮腫治療の採用を阻む障壁となり、治療を必要とする患者の革新的治療へのアクセスを遅らせる可能性があります。さらに、DMEの複雑な性質とその多因子性病態は、的を絞った効果的な治療戦略を開発する上での課題となっています。

市場セグメント分析

世界の黄斑浮腫市場は、疾患タイプ、治療タイプ、エンドユーザー、地域に基づいてセグメント化されています。

レーザー治療は、黄斑浮腫の世界市場シェアの約56.4%を占めています。

眼のレーザー手術は、黄斑浮腫の治療に適用される最も頻繁に使用される治療技術の一つです。これは、黄斑浮腫に対処するために使用できる最も安全な技術の1つであり、したがってこの視点の重要性は高いです。従来の治療および/またはレーザー治療には次のような利点があり、黄斑浮腫の発生を遅らせたり、軽減させたりします。自由診療の治療法には、焦点/グリッド光凝固療法や光線力学的療法（PDT）があり、これらは2つの目的のために戦略を立てた。1つ目は、鋭さをつかさどる網膜の黄斑部に発生する腫れ（浮腫）を抑えることです。

レーザー治療は、網膜の健康にかなり有益な影響を与えながら、黄斑浮腫を軽減するのに役立つため、視力の悪化を食い止めるのに役立ちます。このことは、DMEのような状態を放置しておくと視力がどんどん低下していくような場合に重要です。国立眼科研究所によると、治療によって黄斑浮腫の50～60％は副作用なく完治するといいます。

市場地域別シェア

北米が黄斑浮腫の世界市場シェアの約43.2%を占める

予測期間中、北米地域が最大の市場シェアを占めると予想されます。この地域では、黄斑浮腫の発生率が上昇し、人々の意識が高まっていることが、市場の推進力となっています。

北米では糖尿病の有病率が高いため、糖尿病黄斑浮腫（DME）が黄斑浮腫症例に大きく寄与しています。米国では約770万人が、DMEにつながる可能性のある糖尿病網膜症を患っていると推定されています。全体として、黄斑浮腫は網膜静脈閉塞症や炎症性疾患などさまざまな原因によって起こるが、この地域では糖尿病性網膜症が依然として主な要因です。

高度なヘルスケア施設を有する都市部では、専門医やリソースへのアクセスが良いため、抗VEGF注射のような新しい治療法の採用が普及する可能性があります。北米（特に米国とカナダ）の規制状況は強固で、新しい治療法は承認前に厳格な評価を受ける。このプロセスは、黄斑浮腫の治療における安全性と有効性の高水準の維持に役立っています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • すべての年齢層における糖尿病有病率の増加
    • 世界人口の高齢化
  • 抑制要因
    • 高額な治療費
    • 治療手順が複雑であること
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• アンメットニーズ
• PESTEL分析
• 特許分析
• SWOT分析

第6章 疾患タイプ別

• 糖尿病黄斑浮腫
• 嚢胞様黄斑浮腫

第7章 治療タイプ別

• 注射
• 点眼薬
• レーザー治療
• 眼科手術

第8章 エンドユーザー別

• 眼科センター
• 研究機関および研究所
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Novartis pharmaceuticals
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Regeneron pharmaceuticals
• Roche
• Allergan（ABBVie）
• Bayer
• Alimera sciences
• Bausch Lomb
• Genentech
• Santen Pharmaceuticals
• Opthotech Corporation（*LIST NOT EXHAUSTIVE）

第12章 付録

Overview

The Global Macular Edema Market reached US$ 7,932.69 million in 2023 and is expected to reach US$ 14,874.70 million by 2031, growing at a CAGR of 8.4% during the forecast period 2024-2031.

Macular edema is swelling in part of the retina (the light-sensitive layer of tissue at the back of your eye). People with macular edema may have blurry vision, but treatment can help reduce the swelling and prevent vision loss.

Macular edema happens when blood vessels leak into a part of the retina called the macula. This makes the macula swell, causing blurry vision. Many different conditions can cause macular edema. The most common one is diabetic retinopathy - an eye condition that causes vision loss in people with diabetes. When diabetic retinopathy causes macular edema, it is called diabetic macular edema (DME).

Blurry vision and vision that gets worse over time are the main symptoms of macular edema. Generally, detection of macular edema is done by fluorescein angiogram, optical coherence tomography (OCT), and amsler grid methods.

Market Dynamics: Drivers

Rising prevalence of diabetes in various age groups

Multiple factors drive the demand for the global macular edema market. The rising prevalence of diabetes propels the market growth. Nowadays people affected by diabetes are increasing a lot which is a major cause for the rise of macular edema in people.

Diabetic macular edema is one of the most frequently recorded cases in the overall macular edema cases. According to NCBI, in the US, 3.8% of people who are above the age of 40 years and suffer from diabetes, suffer from diabetic macular edema. In the entire global population who suffer from diabetes, around 4 - 7% of people are being affected by diabetic macular edema.

Restraints

The global macular edema market also faces several challenges and restraints. One key restraint is the high cost of macular edema treatments and therapies, which can limit access to care for patients, particularly in low-income and underserved communities. Additionally, regulatory hurdles and reimbursement policies may create barriers to the adoption of new diabetic macular edema treatments, delaying access to innovative therapies for patients in need. Furthermore, the complex nature of DME and its multifactorial pathogenesis present challenges for developing targeted and effective treatment strategies.

Market Segment Analysis

The global macular edema market is segmented based on disease type, treatment type, end-users, and region.

The segment laser treatment accounted for approximately 56.4% of the global macular edema market share

Laser surgery of the eye is among the most frequently used therapy techniques that are applied to treat macular edema. This is among the safest techniques that can be used to address macular edema, thus the significance of this viewpoint. The Conventional and/or Laser treatment has the following benefits, it slows down the development or reduces macular edema. Free-standing treatments include focal/grid photocoagulation or photodynamic therapy (PDT) which formed strategies for two purposes. The first one was attempted to reduce the swelling (edema) that develops in the macula area of the retina, which is responsible for sharpness.

Laser treatment helps to stop vision from getting any worse because the procedure helps reduce macular edema while having a considerably beneficial impact on the health of the retina. This about is important in conditions such as DME where if the condition is left untreated, the individual will progressively lose their vision. According to National Eye Institute, by treatment 50 to 60% of the macular edema cases can be completely cured without any side effects.

Market Geographical Share

North America accounted for approximately 43.2% of the global macular edema market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of macular edema, and growing awareness among people, in this region, help to propel the market.

Diabetic Macular Edema (DME) is a significant contributor to macular edema cases in North America due to the high prevalence of diabetes. Approximately 7.7 million people in the United States are estimated to have diabetic retinopathy, a condition that can lead to DME. Overall, macular edema can occur due to various causes including retinal vein occlusion and inflammatory conditions, but diabetic retinopathy remains a primary driver in this region.

In urban centers with advanced healthcare facilities, the adoption of newer treatments like anti-VEGF injections may be more prevalent due to better access to specialists and resources. The regulatory landscape in North America (specifically in the United States and Canada) is robust, ensuring that new therapies undergo rigorous evaluation before approval. This process helps maintain high standards of safety and efficacy in treatments for macular edema.

Market Segmentation

By Disease Type

Diabetic macular edema

Cystoid macular edema

By Treatment Type

Injections

Eye Drops

Laser Treatment

Eye surgery

By End Users

Hospitals and clinics

Ophthalmology centers

Research institutes and Laboratories

Others

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the globular macular edema market include Novartis Pharmaceuticals, Regeneron Pharmaceuticals, Roche, Allergan (AbbVie), Bayer, Alimera Sciences, Bausch Lomb, Genentech, Santen Pharmaceutica, and Ophthotech Corporation.

Key Developments

In September 2023, Genentech is developing a Port Delivery System (PDS) that continuously delivers a customized formulation of ranibizumab (Lucentis) directly into the eye over extended periods. This approach aims to reduce the treatment burden for patients with nAMD and potentially other retinal diseases, including macular edema, by providing sustained delivery of the drug and minimizing the need for frequent injections.

In March 2023, Santen Pharmaceuticals announced Positive Phase 3 Results for DE-128 (Sirolimus). Santen reported positive topline results from the Phase 3 DERBY study evaluating DE-128 (sirolimus) intravitreal injection for the treatment of non-infectious uveitis. Sirolimus is an mTOR inhibitor that suppresses inflammation and neovascularization in the eye. The study showed significant improvements in visual acuity and reduction in central subfield thickness compared to sham injections, demonstrating potential benefits in treating macular edema associated with uveitis.

Why Purchase the Report?

To visualize the global macular edema market segmentation based on disease type, treatment type, end-user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of global macular edema market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The global macular edema treatment market report would provide approximately 62 tables, 52 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Disease Type
• 3.2. Snippet by Treatment Type
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing prevalence of diabetes in all age groups
    • 4.1.1.2. Increase in aging of the overall global population
  • 4.1.2. Restraints
    • 4.1.2.1. High cost of treatment
    • 4.1.2.2. The treatment procedures are complicated
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs
• 5.6. PESTEL Analysis
• 5.7. Patent Analysis
• 5.8. SWOT Analysis

6. By Disease Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 6.1.2. Market Attractiveness Index, By Disease Type
• 6.2. Diabetic macular edema
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Cystoid macular edema

7. By Treatment Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 7.1.2. Market Attractiveness Index, By Treatment
• 7.2. Injections
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Eye drops
• 7.4. Laser treatment
• 7.5. Eye surgery

8. By End-Users

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 8.1.2. Market Attractiveness Index, By End-Users
• 8.2. Ophthalmology centers
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Research institutes and laboratories
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. The U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. UK
    • 9.3.6.3. France
    • 9.3.6.4. Italy
    • 9.3.6.5. Spain
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Novartis pharmaceuticals *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Regeneron pharmaceuticals
• 11.3. Roche
• 11.4. Allergan (ABBVie)
• 11.5. Bayer
• 11.6. Alimera sciences
• 11.7. Bausch Lomb
• 11.8. Genentech
• 11.9. Santen Pharmaceuticals
• 11.10. Opthotech Corporation (*LIST NOT EXHAUSTIVE)

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us